Contrast Induced Acute Kidney Injury (CI-AKI) is associated to increased costs and unfavorable results after hemodynamic procedures. Its incidence ranges between 2% and 7% according to the most recent literature. Multiple protection strategies have been analyzed in randomized studies, but no therapy has shown clear benefits. The RenalGuard (RG) is a device that uses furosemide-induced diuresis with...
Peripheral arterial disease is a manifestation of systemic atherosclerotic disease with increasing prevalence. Moreover, this disease is associated with a high risk of mortality and cardiovascular events. Lipoprotein (a) (Lp a)—which has a proatherogenic, proinflammatory, and antifibrinolytic role—has been shown to be related to major cardiovascular events and peripheral vascular events after acute coronary syndromes...
About 4% of the population suffers from tricuspid regurgitation (TR). This disease is associated with hard-to-manage heart failure (HF)—often requiring hospitalization—and with mortality. Surgery in this valve is not simple and has high morbidity and mortality rates due to its comorbidities. Currently, a percutaneous strategy for its resolution is under development, but we still do...
The benefit of the transradial approach in percutaneous interventions is well known. Its main limitation is radial artery occlusion (RAO) which would compromise the artery for future use in percutaneous procedures. Even though it is clinically silent, reported cases might reach 33%. More recently, the distal radial access (DRA) has surged as an alternative to...
Peripheral vascular disease (PVD) has been under-studied and under-recognized in comparison with ischemic heart disease and stroke, despite its well-known impact on quality of life and its associated morbidity and mortality. According to a systematic review, it was estimated that in 2015 about 238 million people globally had PVD. This number is on the rise....
Conventional transradial access (TRA) is already established as the access of choice for percutaneous coronary procedures, regardless of clinical presentation. This choice is based on multiple randomized studies and meta-analyses that have shown reduced bleeding at the puncture site, less vascular complications, and benefits on mortality (mainly in high-risk patients). The practicality of recovery allows...
Dual antiplatelet therapy (DAPT) after PCI with DES has shown noticeable reduction of thrombotic events, especially in acute coronary syndromes (ACS). However, this therapy encompasses increased bleeding, especially in elderly patients increasingly undergoing percutaneous intervention. Even though most bleeding events might not be fatal (many of them are mostly digestive) they do involve higher hospitalization...
In Europe and the US, aortic stenosis is the most frequent cause of valve intervention, both surgical and percutaneous, and, as we all know, TAVR has made great progress in this regard. However, this technique has an Achilles heel when it comes to self-expandable valves: definite pacemaker implantation rate is 3 to 4 times higher...
Currently, edge-to-edge therapy with MitraClip has demonstrated efficacy and safety for the treatment of patients with degenerative or functional mitral regurgitation who are at high risk for surgery. However, device-related complications are still present—though their frequency is subsiding due to greater experience, 3D doppler echocardiography development, and technological advancements: loss of leaflet insertion (LLI), single...
Learn about the Latin American Registry of the Percutaneous Intervention of Coronary Bifurcations January 2022 report. The registry has already enrolled over 700 patients, which makes us most proud. More than 23 centers from Argentina, Mexico, Peru, Colombia, Ecuador, Bolivia, and Guatemala have joined the registry. For those who still haven’t heard of it, LATAM...